PRODUCT INFORMATION



Goserelin (acetate)

Item No. 24071

CAS Registry No.: Formal Name:	145781-92-6 2-(aminocarbonyl)hydrazide-6-[O-	OH	н о л Д
	(1,1-dimethylethyl)-D-serine]-1-		
	9-luteinizing hormone-releasing	H HO N N N	
	factor (swine), acetate		
MF:	$C_{59}H_{84}N_{18}O_{14} \bullet XC_{2}H_{4}O_{2}$		
FW:	1,329.5		
Purity:	≥98%		HN
UV/Vis.:	λ _{max} : 222, 282 nm		INF12
Supplied as:	A crystalline solid		
Storage:	-20°C		
Stability:	≥4 years	н	

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Goserelin (acetate) is supplied as a crystalline solid. A stock solution may be made by dissolving the goserelin (acetate) in the solvent of choice, which should be purged with an inert gas. Goserelin (acetate) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of goserelin (acetate) in ethanol is approximately 0.25 mg/ml and approximately 30 mg/ml in DMSO and DMF.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of goserelin (acetate) can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of goserelin (acetate) in PBS (pH 7.2) is approximately 10 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

Goserelin is a synthetic gonadotropin-releasing hormone (GNRH) agonist that binds to the GNRH receptor (GNRHR; $K_i = 1.6$ nM in CHO cells expressing the human receptor).¹ It binds to mouse pituitary α T3-1 cells and human placenta (K₄s = 2 and 580 nM, respectively) and increases intracellular calcium in α T3-1 cells.² Goserelin induces testosterone production in vitro within 4 h in rat Leydig cells (ED₅₀ = 83 nM) but decreases testosterone plasma level in vivo in rats over a period of 2 to 24 weeks.^{3,4} It inhibits tumor growth in a DU145 human prostate carcinoma mouse xenograft model when administered at a dose of 100 μg per day.⁵ Formulations containing goserelin have been used in the treatment of hormone-dependent breast and prostate cancers, as well as endometriosis and uterine fibroids.

References

- 1. Nederpelt, I., Georgi, V., Schiele, F., et al. Br. J. Pharmacol. 173(1), 128-141 (2016).
- 2. Chatzaki, E., Bax, C.M., Eidne, K.A., et al. Cancer Res. 56(9), 2059-2065 (1996).
- 3. Sullivan, M.H. and Cooke, B.A. Biochem. J. 218(2), 621-624 (1984).
- 4. Ward, J.A., Furr, B.J., Valcaccia, B., et al. J. Androl. 10(6), 478-486 (1989).
- 5. Dondi, D., Moretti, R.M., Montagnani, M.M., et al. Int. J. Cancer 76(4), 506-511 (1998).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFFTY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/11/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM